SCHEMBL206164

SCHEMBL206164

COC(=O)c1cccc(O)c1[N+](=O)[O-]

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TSHR P16473 2/20 0.58
LMNA P02545 1/20 0.58
CA1 P00915 4/20 0.52
CA2 P00918 4/20 0.52
CA9 Q16790 4/20 0.52
CA12 O43570 3/20 0.52
CA7 P43166 3/20 0.52
CA14 Q9ULX7 3/20 0.52
GPR35 Q9HC97 1/20 0.51
SMN1; SMN2 Q16637 4/20 0.50
ALDH1A1 P00352 2/20 0.50
MEN1 O00255 2/20 0.50
KMT2A Q03164 2/20 0.50
POLB P06746 2/20 0.46
HPGD P15428 1/20 0.46
GAA P10253 1/20 0.44
CFTR P13569 1/20 0.43
HSD17B10 Q99714 1/20 0.43
KCNMA1 Q12791 2/20 0.43
CA5A P35218 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30662861 1.00 TSHR (0.58) TSHRLMNACA1CA2CA9
SCHEMBL8421994 0.90 ALDH1A1 (0.55) TSHRLMNASMN1; SMN2ALDH1A1MEN1
SCHEMBL6551228 0.85 TSHR (0.56) TSHRLMNASMN1; SMN2ALDH1A1MEN1
SCHEMBL6988348 0.84 ALDH1A1 (0.48) TSHRLMNASMN1; SMN2ALDH1A1MEN1
SCHEMBL2521491 0.83 HPGD (0.52) TSHRLMNASMN1; SMN2ALDH1A1MEN1
SCHEMBL27746873 0.83 ALDH1A1 (0.61) TSHRLMNACA1CA2CA9
SCHEMBL16957915 0.83 ALDH1A1 (0.50) TSHRLMNASMN1; SMN2ALDH1A1MEN1
SCHEMBL1032670 0.83 ALDH1A1 (0.68) TSHRLMNASMN1; SMN2ALDH1A1MEN1
SCHEMBL7369896 0.83 TSHR (0.54) TSHRLMNAGPR35SMN1; SMN2ALDH1A1
SCHEMBL31014185 0.83 GPR35 (0.47) TSHRLMNACA1CA2CA9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 155 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260132133-A1 MACROCYCLIC HETEROCYCLES AND USES THEREOF KUMQUAT BIOSCIENCES INC (US) 2026-05-14 US disclosed
US-12466820-B2 Amino quinazoline derivatives as P2X3 inhibitors CHIESI FARMACEUTICI S.P.A. (IT) 2025-11-11 US disclosed
US-20250154169-A1 COMPOUNDS AND METHODS FOR MODULATING SPLICING REMIX THERAPEUTICS INC. 2025-05-15 US disclosed
WO-2025056073-A1 INDAZOLONE COMPOUND, PREPARATION METHOD THEREFOR, PHARMACEUTICAL COMPOSITION, AND USE 中国科学院上海药物研究所 2025-03-20 WO disclosed
CN-119613374-A Indazolone compound, preparation method thereof, pharmaceutical composition and application thereof 中国科学院上海药物研究所 2025-03-14 CN disclosed
US-12195465-B2 Macrocyclic heterocycles and uses thereof KUMQUAT BIOSCIENCES INC. (US) 2025-01-14 US disclosed
CN-119095849-A Macrocyclic heterocycles and uses thereof 金橘生物科技公司 2024-12-06 CN disclosed
CN-116075500-B Capacitor with improved capacitance 基美电子公司 2024-11-26 CN disclosed
CN-118451068-A Tri-fused ring derivative inhibitor, preparation method and application thereof 上海翰森生物医药科技有限公司 2024-08-06 CN disclosed
EP-4395892-A1 COMPOUNDS AND METHODS FOR MODULATING SPLICING Remix Therapeutics Inc. (US) 2024-07-10 EP disclosed
EP-0879820-B1 Benzamide analogues, useful as PARP (ADP-Ribosyltransferase, ADPRT) DNA repair enzyme inhibitors UNIV NEWCASTLE VENTURES LTD (GB) 2001-12-12 EP disclosed
US-6316455-B1 Method of improving the effectiveness of a cytotoxic drug or radiotherapy using a quinazolinone compound NEWCASTLE UNIVERSITY VENTURES LIMITED (GB) 2001-11-13 US disclosed
US-6015827-A Benzoxazole-4-carboxamides and their use in inhibiting poly (adp-ribose) polymerase activity and improving cytotoxic effectiveness of cytotoxic drugs or radiotherapy NEWCASTLE UNIVERSITY VENTURES LIMITED 2000-01-18 US disclosed
US-5847231-A Selective nitration of phenol derivatives JUNSEI CHEMICAL CO., LTD. (JP) 1998-12-08 US disclosed
EP-0879820-A1 Benzamide analogues, useful as PARP (ADP-Ribosyltransferase, ADPRT) DNA repair enzyme inhibitors NEWCASTLE UNIVERSITY VENTURES LIMITED (GB) 1998-11-25 EP disclosed
US-5756510-A POTENTIATE EFFECTS OF CYTOTOXIC DRUGS OR RADIOTHERAPY NEWCASTLE UNIVERSITY VENTURES LIMITED (GB) 1998-05-26 US disclosed
CN-1174829-A Selective nitration of phenol derivatives JUNSEI CHEMICAL (JP) 1998-03-04 CN disclosed
CN-1143358-A Benzamide analogs, useful as parp (ADP-ribosyltransferase, ADRPT) DNA repair enzyme inhibitors UNIV NEWCASTLE VENTURES LTD (GB) 1997-02-19 CN disclosed
EP-0749415-A1 BENZAMIDE ANALOGS, USEFUL AS PARP (ADP-RIBOSYLTRANSFERASE, ADPRT) DNA REPAIR ENZYME INHIBITORS NEWCASTLE UNIVERSITY VENTURES LIMITED (GB) 1996-12-27 EP disclosed
WO-1995024379-A1 BENZAMIDE ANALOGS, USEFUL AS PARP (ADP-RIBOSYLTRANSFERASE, ADPRT) DNA REPAIR ENZYME INHIBITORS NEWCASTLE UNIVERSITY VENTURES LIMITED (GB) 1995-09-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12466820-B2 Amino quinazoline derivatives as P2X3 inhibitors P2RX3, P2RX5, P2RX1 TSHR 3428/4885LMNA 3348/4885CA1 4501/4885
US-20260132133-A1 MACROCYCLIC HETEROCYCLES AND USES THEREOF KRAS, HRAS, BCL6 TSHR 371/4885LMNA 1095/4885CA1 1126/4885
US-12195465-B2 Macrocyclic heterocycles and uses thereof HRAS, KRAS, TP53 TSHR 2022/4885LMNA 2455/4885CA1 3160/4885
US-20250154169-A1 COMPOUNDS AND METHODS FOR MODULATING SPLICING RBM17, SNRPA, SNRPA1 TSHR 4252/4885LMNA 324/4885CA1 4082/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.